FDA Clearance Tracker · P150038-S014
Exablate Model 4000 Type 1.0 and 1.1 System (Exablate Neuro)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Oct 29, 2021
Approved
Time to decision
212 days
Received Mar 31, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P150038-S014
- Device name
- Exablate Model 4000 Type 1.0 and 1.1 System (Exablate Neuro)
- Applicant
- Insightec
- Applicant location
- Tirat Carmel
- Received
- Mar 31, 2021
- Decided
- Oct 29, 2021
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150038
Device type
- Device type
- MR-guided focused ultrasound system (POH)
- Device class
- Class III
- Specialty
- Neurology & Neurosurgery
FDA's approval statement
As written in FDA's record.
Approval for the Exablate Neuro. The device is indicated for use in the unilateral pallidotomy of patients with advanced, idiopathic Parkinsons disease with medication-refractory moderate to severe motor complications as an adjunct to Parkinsons disease medication treatment. Patients must be at least age 30. The designated area in the brain responsible for the movement disorder symptoms [globus pallidus (GPi)] must be identified and accessible for targeted thermal ablation by the Exablate device.
Source documents
Other decisions for Insightec
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Exablate Model 4000 Type-1 SystemPMA supplement
P150038-S037 · Decided Jul 3, 2025 · 352 days after receipt · Panel Track
Device type: MR-guided focused ultrasound system (POH) · Neurology & Neurosurgery
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.